. 2021 Nov 22;143(48):20224–20240. doi: 10.1021/jacs.1c08630

Table 2. Half-Maximal Inhibitory Concentrations (IC₅₀/μM) of Pt1, Pt2, and Cisplatin toward PC3 Cancer Cells in the Dark and on Exposure to Blue Light, and Standard Deviations from Duplicates of Triplicate Determinations^a.

complex	dark IC₅₀^b (μM)	photo IC₅₀^c (μM)
Pt1	>100^d	55.6 ± 0.9
Pt2	>100^d	6.48 ± 0.84
cisplatin	>100^d	>100^d

100 μM concentration (higher than the test range) is deemed inactive.

1 h exposure to complexes to allow uptake (protected from light) followed by a further 1 h protected from light and 24 h recovery in fresh medium.

1 h exposure to complexes to allow uptake (protected from light) followed by 1 h irradiation with blue light (λ = 465 nm, 17 J/cm²) and 24 h recovery in fresh medium.

Exceeds the concentration range used for IC₅₀ determination.

Table 2. Half-Maximal Inhibitory Concentrations (IC50/μM) of Pt1, Pt2, and Cisplatin toward PC3 Cancer Cells in the Dark and on Exposure to Blue Light, and Standard Deviations from Duplicates of Triplicate Determinationsa.

Table 2. Half-Maximal Inhibitory Concentrations (IC₅₀/μM) of Pt1, Pt2, and Cisplatin toward PC3 Cancer Cells in the Dark and on Exposure to Blue Light, and Standard Deviations from Duplicates of Triplicate Determinations^a.